Abstract
The prognosis for malignant gliomas remains poor despite multimodality therapy. An increased understanding of the molecular pathogenesis involved in glioma development and growth has resulted in development of agents that specifically target these molecular processes and pathways. Except for inhibitors of the vascular endothelial growth factor pathway, results from most single agent trials have been modest at best. Tailoring therapy to the individual patients is an attractive strategy although most studies have failed to determine predictive biomarkers. Numerous novel agents, multitargeted agents, and combination therapies are now in clinical trials for malignant glioma.
Keywords: Targeted therapy, malignant glioma, angiogenesis, clinical trials, multi-targeted therapy, "malignant gliomas", cellular signaling kinases
Current Signal Transduction Therapy
Title:Application of Targeted Therapy to Malignant Gliomas and Response to Treatment
Volume: 8 Issue: 1
Author(s): Eudocia Q. Lee, Andrew D. Norden, Jan Drappatz and Patrick Y. Wen
Affiliation:
Keywords: Targeted therapy, malignant glioma, angiogenesis, clinical trials, multi-targeted therapy, "malignant gliomas", cellular signaling kinases
Abstract: The prognosis for malignant gliomas remains poor despite multimodality therapy. An increased understanding of the molecular pathogenesis involved in glioma development and growth has resulted in development of agents that specifically target these molecular processes and pathways. Except for inhibitors of the vascular endothelial growth factor pathway, results from most single agent trials have been modest at best. Tailoring therapy to the individual patients is an attractive strategy although most studies have failed to determine predictive biomarkers. Numerous novel agents, multitargeted agents, and combination therapies are now in clinical trials for malignant glioma.
Export Options
About this article
Cite this article as:
Q. Lee Eudocia, D. Norden Andrew, Drappatz Jan and Y. Wen Patrick, Application of Targeted Therapy to Malignant Gliomas and Response to Treatment, Current Signal Transduction Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574362411308010004
DOI https://dx.doi.org/10.2174/1574362411308010004 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Brain Imaging and Automatic Analysis in Neurological and Psychiatric Diseases – Part II
CNS & Neurological Disorders - Drug Targets Pathophysiological Role of Mitochondrial Potassium Channels and their Modulation by Drugs
Current Medicinal Chemistry Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology Rho GTPase Activating Proteins in Cancer Phenotypes
Current Protein & Peptide Science Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery Transforming Growth Factor Beta in Pancreatic Cancer
Current Pharmaceutical Biotechnology Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry Applications of Muscle Electroporation Gene Therapy
Current Gene Therapy Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets Novel Beta-Lactam Antibiotics Derivatives: Their New Applications as Gene Reporters, Antitumor Prodrugs and Enzyme Inhibitors
Mini-Reviews in Medicinal Chemistry Saponins-uptake and Targeting Issues for Brain-specific Delivery for Enhanced Cell Death Induction in Glioblastoma
Letters in Drug Design & Discovery Cannabinoids and Sensory Neurones
Current Neuropharmacology Translating Mismatch Repair Mechanism into Cancer Care
Current Drug Targets EDITORIAL [Hot topic: New Therapeutic Advances and Perspectives in Tumour Angiogenesis (Guest Editor: Eddy Pasquier)]
Current Cancer Drug Targets Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Anesthetic Cardioprotection in Relation to Mitochondria: Basic Science
Current Pharmaceutical Design Glutamate Dehydrogenase as a Promising Target for Hyperinsulinism Hyperammonemia Syndrome Therapy
Current Medicinal Chemistry Drug-Resistance in Central Nervous System Tumors: From the Traditional Cell-Resistance Model to the Genetically Driven Approaches on Therapy
Current Pharmaceutical Biotechnology